Biomarker & Intervention Discovery
Benign Prostatic Hyperplasia (BPH)
Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.
Spontaneous remissionProgressive natural history; symptoms worsen in 50-60% over 5 years without treatment; spontaneous improvement in…
Best-intervention remissionCombination alpha-blocker + 5-ARI (tamsulosin + dutasteride): reduces prostate volume 25-30%, acute urinary retention…
Gap sizeModerate — treatment is effective but procedure uptake and pharmacotherapy titration is suboptimal; many patients…
Primary barrierpractice
Full remission profile →
Remission & chronicity
Spontaneous remission
Progressive natural history; symptoms worsen in 50-60% over 5 years without treatment; spontaneous improvement in 20-30% (particularly mild symptoms); acute urinary retention risk ~1-2%/year
Best-intervention remission
Combination alpha-blocker + 5-ARI (tamsulosin + dutasteride): reduces prostate volume 25-30%, acute urinary retention risk 67% (CombAT trial); minimally invasive procedures (Rezum, Urolift, Aquablation): IPSS improvement 50-60%, preserving ejaculatory function better than TURP; TURP: gold standard, 70-80% symptom improvement
Gap size
Moderate — treatment is effective but procedure uptake and pharmacotherapy titration is suboptimal; many patients overtreated with TURP when less invasive options appropriate
Alpha-blockers provide symptomatic relief but do not address prostate volume in large glands (5-ARI needed); TURP remains widely used when Rezum/Urolift preserve sexual function with similar efficacy; pharmacotherapy stepped-up without referral in cases where early MIS procedure would preserve more function
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC.
Agents ranked: ● Clinical >
● Mechanistic >
● Correlative.
Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm
Clinical Trials
Recruiting and recently completed trials from ClinicalTrials.gov.
Data retrieved 2026-07-06.
No recent clinical trials found on ClinicalTrials.gov for this condition.
Agents Found By Disease-Level Search
Searched directly from “Benign Prostatic Hyperplasia (BPH)” via ClinicalTrials.gov interventions and Open Targets'
disease→drug data — independent of the 0-gene target panel above.
This surfaces agents whose mechanism doesn't route through a curated gene (combination
therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."